Abiopharma

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

American Shared Hospital Services Announces Third Quarter Financial Results Conference Call

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma

Immunocore reports third quarter financial results and provides a business update

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025